Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

HC Wainwright reiterated a “buy” rating and set a $102.00 target price on shares of Viking Therapeutics in a report on Friday, January 17th. B. Riley started coverage on shares of Viking ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising obesity-drug program and its potential appeal to a deep-pocketed ...

It has been a little more than two months since my last Viking Therapeutics ... Furthermore, I have only mentioned VK2735’s potential… we haven’t added in the company’s VK2809 program ...

Viking Therapeutics(NASDAQ ... Viking focuses on GIP/GLP-1 receptor agonists and has a candidate, VK2735, in late-stage clinical trials. As an injectable (like the Novo Nordisk and Lilly ...

Viking's obesity-drug program is progressing well. Now management is thinking about manufacturing tie-ups. Viking Therapeutics Inc ... of its oral obesity drug VK2735, with a data readout expected ...

The real Holy Grail is a weight-loss-in-a-pill formulation, which has investors very interested in Viking Therapeutics‘ (NASDAQ:VKTX) VK2735, which is showing better efficacy than Novo Nordisk ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets ...